Back to search

Netherlands· NL-1982a3098c9b

Kaftrio 37,5 mg/25 mg/50 mg, filmomhulde tabletten

A ivacaftor, tezacaftor and elexacaftor product containing elexacaftor + ivacaftor + tezacaftor, registered in Netherlands by Vertex Pharmaceuticals (Ireland) Limited. The same ATC class is registered in 14 of our 19 countries.

ATC R07AX32

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedKaftrio 37,5 mg/25 mg/50 mg, filmomhu…ATCR07AX32REGISTER NO.NL-1982a3098c9bPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Ivacaftor, tezacaftor and elexacaftor is registered in 14 of 19 countries.

Countries holding a registration under ATC R07AX32 (ivacaftor, tezacaftor and elexacaftor), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose

Ivacaftor, tezacaftor and elexacaftor · ATC R07AX32

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ELEXACAFTOR + IVACAFTOR + TEZACAFTOR
Manufacturer
Vertex Pharmaceuticals (Ireland) Limited
Country
Netherlands (NL)
ATC code
R07AX32
ATC class
Ivacaftor, tezacaftor and elexacaftor
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/20/1468

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

14 interactions on record for ivacaftor, tezacaftor and elexacaftor.

Graded by severity as the source publishes them — 14 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ivacaftor, tezacaftor and elexacaftor · interactions on record

14 records

  • 14 moderate

Most severe, free to view

  • RifaximinA07AA11moderate
  • EmpagliflozinA10BK03moderate
  • RepaglinideA10BX02moderate
  • EmpagliflozinA10BX12moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eaf59ac2-547f-4d2f-8d37-cca5be848ecb
GET /v1/drugs/eaf59ac2-547f-4d2f-8d37-cca5be848ecb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/kaftrio-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Ivacaftor, Tezacaftor And Elexacaftor",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128110",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "HYPROLOSE (E 463)",
    "HYPROMELLOSE (E 464)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "HYPROMELLOSEACETAATSUCCINAAT",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMLAURILSULFAAT",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "ELEXACAFTOR",
    "IVACAFTOR",
    "TEZACAFTOR"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/01/07",
  "procedure_number": "EMEA/H/C/005269",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/20/1468",
  "additional_monitoring": "N"
}

See everything about ivacaftor, tezacaftor and elexacaftor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.